Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Performance Evaluation of a Urine-based Methylation Assay for Urothelial Carcinoma in Patients With Hematuria: A Prospective, Multi-center Cohort Study

NCT06912672 is registered in ClinicalTrials.gov with Shanghai Epiprobe Biotechnology Co., Ltd. as lead sponsor.

NCT NCT06912672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06912672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Performance Evaluation of a Urine-based Methylation Assay for Urothelial Carcinoma in Patients With Hematuria: A Prospective, Multi-center Cohort Study
Lead sponsor
Shanghai Epiprobe Biotechnology Co., Ltd.
Phase
Observational
Overall status
Not yet recruiting
Start date
May 1, 2025
Completion date
December 31, 2026
Enrollment
1,500 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial carcinoma